SCHEMBL5451784

SCHEMBL5451784

CC(C)Cn1c(C(NC(=O)O)C(C)(C)C)nc2cnc3ccccc3c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.42
ALDH1A1 P00352 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TLR7 Q9NYK1 3/20 0.37
POLB P06746 2/20 0.37
HRH2 P25021 1/20 0.37
ADRA1D P25100 1/20 0.37
HTR2A P28223 1/20 0.37
ADORA2A P29274 1/20 0.37
ADRA1A P35348 1/20 0.37
NUDT1 P36639 1/20 0.37
HTR2B P41595 1/20 0.37
PDE4D Q08499 1/20 0.37
KCNH2 Q12809 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPT P10636 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459030 0.84 TLR7 (0.51) LMNATLR7POLBHRH2ADRA1D
SCHEMBL2040358 0.82 LMNA (0.60) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5808827 0.78 LMNA (0.53) LMNAALDH1A1SMN1; SMN2TLR7POLB
SCHEMBL6722237 0.78 SMN1; SMN2 (0.45) LMNAALDH1A1SMN1; SMN2TLR7POLB
SCHEMBL6723854 0.78 NPSR1 (0.52) LMNAALDH1A1SMN1; SMN2TLR7POLB
SCHEMBL6726678 0.76 ALDH1A1 (0.39) LMNAALDH1A1SMN1; SMN2TLR7POLB
SCHEMBL6724014 0.76 SMN1; SMN2 (0.47) LMNAALDH1A1SMN1; SMN2TLR7POLB
SCHEMBL6722346 0.75 TLR7 (0.40) LMNAALDH1A1SMN1; SMN2TLR7POLB
SCHEMBL6724108 0.75 ALDH1A1 (0.39) LMNAALDH1A1SMN1; SMN2TLR7POLB
SCHEMBL10739564 0.75 ALDH1A1 (0.64) LMNAALDH1A1SMN1; SMN2TLR7POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods COLEY PHARMACEUTICAL GROUP, INC. 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods IL2, IL4, IRF3 LMNA 4207/4885ALDH1A1 2134/4885SMN1; SMN2 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.